Form 4: Arcellx Director Olivia Ware Granted Stock Options Valued at $63.68 Per Share

Arcellx, Inc. Director Olivia C. Ware was granted 9,174 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Summary

• Olivia C. Ware, a Director of Arcellx, Inc. (ACLX), acquired 9,174 derivative securities in the form of stock options on May 29, 2025.
• The stock options have an exercise price of $63.68 per share.
• Each option represents the right to buy one share of Arcellx Common Stock, totaling 9,174 underlying shares.
• The options are subject to a vesting schedule where 100% of the shares will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, contingent upon Ms. Ware's continued service as a Service Provider.
• The expiration date for these stock options is May 29, 2035.
• The transaction was reported as a direct beneficial ownership.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with those of shareholders, incentivizing long-term performance. This is a routine compensation event and does not indicate any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance and value creation.
• This equity grant is part of a standard compensation package, indicating a commitment to retaining and motivating key personnel.

Future Outlook

This Form 4 filing primarily reports a compensation event and does not provide specific forward-looking statements or guidance regarding the company's operational or financial performance. The vesting schedule indicates a future milestone for the options.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align long-term incentives with company performance.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to continued service, is typical for equity incentive plans designed to retain talent and encourage long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of 9,174 stock options to Olivia C. Ware, a Director of Arcellx, Inc., constitutes a related party transaction as part of her compensation package.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall company morale and talent retention.

Next Steps

• The stock options will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, subject to continued service.
• Following vesting, the options may be exercised by the reporting person at the specified exercise price until their expiration date of May 29, 2035.

Key Dates

Recommendation

Keywords

Arcellx, ACLX, Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Incentive Plan, Beneficial Ownership